Kanghong Pharmaceutical

The Ministry of Industry and Information Technology announced the first batch of national demonstration bases for emerging industry development.

The 2026 China Pharmaceutical Conference in Jinan awarded the 21st China Pharmaceutical Association Scientific Technology Award.

Kanghong Pharmaceutical Group, founded in 1996, is a large pharmaceutical company specializing in research, production, sales, and after-sales service of traditional Chinese medicine, chemical drugs, and biological products. Its headquarters is in Chengdu, Sichuan, with multiple production bases across China.

Kanghong Pharmaceutical expands Conbercept’s use to treat severe retinopathy of prematurity (ROP) in infants, covering **Zone I (stages 1+ to 3+), Zone II (stage 3+), and aggressive posterior ROP (AP-ROP)**. The **NMPA approval** makes this the fifth indication for the company’s **Category 1 biologic drug**, broadening its application beyond adult retinal diseases. Conbercept, an ophthalmic injection, now targets neonatal eye disorders with regulatory backing in China.

Sep 2026Insight, China's Pharmaceutical IndustryNews article

Kanghong Pharmaceutical and Vanotech report that their drug candidate **KH607** meets the primary endpoint in a Phase 2b trial for **major depressive disorder**, showing strong efficacy and a favorable safety profile. The results advance KH607 toward planned **Phase 3 testing**. The companies highlight the potential of KH607 as a novel treatment option in psychiatric care.

May 2026BioSpaceNews article

Chengdu Kanghong Pharmaceutical Group secures **National Medical Products Administration (NMPA) approval** for clinical trials of its **Category 1 drug KH607**, targeting **postpartum depression**. The company, listed on the Shenzhen Stock Exchange (SHE: 002773), advances its pipeline with this regulatory milestone. KH607 represents a potential new treatment option for a condition affecting millions globally.

May 2025Insight, China's Pharmaceutical IndustryNews article

Kanghong Pharmaceutical secures implicit approval from China’s National Medical Products Administration (NMPA) for clinical trials of its **KH629 tablets**, a Class 1 new drug targeting **adult non-alcoholic steatohepatitis (NASH)**. The drug, a **selective agonist of the thy** receptor, is independently developed by the company. This approval marks a key milestone for Kanghong Pharmaceutical’s (SHE: 002773) pipeline of innovative treatments.

Oct 2024Insight, China's Pharmaceutical IndustryNews article